Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients

Margo van Campenhout; Willem Pieter Brouwer; Gertine van Oord; Q Xie; Q Zhang; N Zhang; S Guo; F Tabak; A Streinu-Cercel; Johnny Wang; Suzan Pas; Milan Sonneveld; Rob de Knegt; Andre Boonstra; Bettina Hansen; HLA Janssen

doi:10.1016/j.cmi.2016.02.002

Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients

Margo van Campenhout, Willem Pieter Brouwer, Gertine van Oord, Q Xie, Q Zhang, N Zhang, S Guo, F Tabak, A Streinu-Cercel, Johnny Wang, Suzan Pas, Milan Sonneveld, Rob de Knegt, Andre Boonstra, Bettina Hansen, HLA Janssen

Research output: Contribution to journal › Article › Academic

26 Citations (Scopus)

Abstract

Hepatitis B core-related antigen (HBcrAg), a new serum marker, may be useful in monitoring chronic hepatitis B infection. HBcrAg was measured in 175 hepatitis B e antigen-positive patients treated with entecavir (ETV) with or without peginterferon (PEG-IFN) add-on therapy. Decline in HBcrAg was stronger in patients with vs. without combined response (ETV: -3.22 vs. -1.71 log U/mL, p <0.001; PEG-IFN add-on: -3.16 vs. -1.83 IU/mL, p <0.001) and in patients with vs. without hepatitis B surface antigen (HBsAg) response (ETV: -2.60 vs. -1.74 log U/mL, p <0.001; PEG-IFN addon: -2.38 vs. -2.15 log U/mL, p = 0.31). HBcrAg was associated with combined response (adjusted odds ratio 0.3, 95% confidence interval 0.2-0.5, p <0.001), but was not superior to quantitative HBsAg (qHBsAg). (C) 2016 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.

Original language	Undefined/Unknown
Journal	Clinical Microbiology and Infection
Volume	22
Issue number	6
DOIs	https://doi.org/10.1016/j.cmi.2016.02.002
Publication status	Published - 2016

Research programs

EMC MM-04-20-02-A
EMC MM-04-27-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cmi.2016.02.002

http://hdl.handle.net/1765/86207

Cite this

van Campenhout, M., Brouwer, W. P., van Oord, G., Xie, Q., Zhang, Q., Zhang, N., Guo, S., Tabak, F., Streinu-Cercel, A., Wang, J., Pas, S., Sonneveld, M., de Knegt, R., Boonstra, A., Hansen, B., & Janssen, HLA. (2016). Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients. Clinical Microbiology and Infection, 22(6). https://doi.org/10.1016/j.cmi.2016.02.002

@article{1af9c5f586024e1498a5cb30668a14e1,

title = "Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients",

abstract = "Hepatitis B core-related antigen (HBcrAg), a new serum marker, may be useful in monitoring chronic hepatitis B infection. HBcrAg was measured in 175 hepatitis B e antigen-positive patients treated with entecavir (ETV) with or without peginterferon (PEG-IFN) add-on therapy. Decline in HBcrAg was stronger in patients with vs. without combined response (ETV: -3.22 vs. -1.71 log U/mL, p <0.001; PEG-IFN add-on: -3.16 vs. -1.83 IU/mL, p <0.001) and in patients with vs. without hepatitis B surface antigen (HBsAg) response (ETV: -2.60 vs. -1.74 log U/mL, p <0.001; PEG-IFN addon: -2.38 vs. -2.15 log U/mL, p = 0.31). HBcrAg was associated with combined response (adjusted odds ratio 0.3, 95% confidence interval 0.2-0.5, p <0.001), but was not superior to quantitative HBsAg (qHBsAg). (C) 2016 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.",

author = "{van Campenhout}, Margo and Brouwer, {Willem Pieter} and {van Oord}, Gertine and Q Xie and Q Zhang and N Zhang and S Guo and F Tabak and A Streinu-Cercel and Johnny Wang and Suzan Pas and Milan Sonneveld and {de Knegt}, Rob and Andre Boonstra and Bettina Hansen and HLA Janssen",

year = "2016",

doi = "10.1016/j.cmi.2016.02.002",

language = "Undefined/Unknown",

volume = "22",

journal = "Clinical Microbiology and Infection",

issn = "1198-743X",

publisher = "Elsevier",

number = "6",

}

van Campenhout, M, Brouwer, WP , van Oord, G, Xie, Q, Zhang, Q, Zhang, N, Guo, S, Tabak, F, Streinu-Cercel, A, Wang, J, Pas, S, Sonneveld, M , de Knegt, R , Boonstra, A , Hansen, B & Janssen, HLA 2016, 'Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients', Clinical Microbiology and Infection, vol. 22, no. 6. https://doi.org/10.1016/j.cmi.2016.02.002

Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients. / van Campenhout, Margo; Brouwer, Willem Pieter ; van Oord, Gertine et al.
In: Clinical Microbiology and Infection, Vol. 22, No. 6, 2016.

Research output: Contribution to journal › Article › Academic

TY - JOUR

T1 - Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients

AU - van Campenhout, Margo

AU - Brouwer, Willem Pieter

AU - van Oord, Gertine

AU - Xie, Q

AU - Zhang, Q

AU - Zhang, N

AU - Guo, S

AU - Tabak, F

AU - Streinu-Cercel, A

AU - Wang, Johnny

AU - Pas, Suzan

AU - Sonneveld, Milan

AU - de Knegt, Rob

AU - Boonstra, Andre

AU - Hansen, Bettina

AU - Janssen, HLA

PY - 2016

Y1 - 2016

N2 - Hepatitis B core-related antigen (HBcrAg), a new serum marker, may be useful in monitoring chronic hepatitis B infection. HBcrAg was measured in 175 hepatitis B e antigen-positive patients treated with entecavir (ETV) with or without peginterferon (PEG-IFN) add-on therapy. Decline in HBcrAg was stronger in patients with vs. without combined response (ETV: -3.22 vs. -1.71 log U/mL, p <0.001; PEG-IFN add-on: -3.16 vs. -1.83 IU/mL, p <0.001) and in patients with vs. without hepatitis B surface antigen (HBsAg) response (ETV: -2.60 vs. -1.74 log U/mL, p <0.001; PEG-IFN addon: -2.38 vs. -2.15 log U/mL, p = 0.31). HBcrAg was associated with combined response (adjusted odds ratio 0.3, 95% confidence interval 0.2-0.5, p <0.001), but was not superior to quantitative HBsAg (qHBsAg). (C) 2016 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.

AB - Hepatitis B core-related antigen (HBcrAg), a new serum marker, may be useful in monitoring chronic hepatitis B infection. HBcrAg was measured in 175 hepatitis B e antigen-positive patients treated with entecavir (ETV) with or without peginterferon (PEG-IFN) add-on therapy. Decline in HBcrAg was stronger in patients with vs. without combined response (ETV: -3.22 vs. -1.71 log U/mL, p <0.001; PEG-IFN add-on: -3.16 vs. -1.83 IU/mL, p <0.001) and in patients with vs. without hepatitis B surface antigen (HBsAg) response (ETV: -2.60 vs. -1.74 log U/mL, p <0.001; PEG-IFN addon: -2.38 vs. -2.15 log U/mL, p = 0.31). HBcrAg was associated with combined response (adjusted odds ratio 0.3, 95% confidence interval 0.2-0.5, p <0.001), but was not superior to quantitative HBsAg (qHBsAg). (C) 2016 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.

U2 - 10.1016/j.cmi.2016.02.002

DO - 10.1016/j.cmi.2016.02.002

M3 - Article

C2 - 26898481

SN - 1198-743X

VL - 22

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

IS - 6

ER -